We compared mucociliary clearance and forced expiratory volume in one second (FEVI) in healthy subjects and patients with mild to moderate bronchial asthma after inhalation of equal doses of terbutaline from a metered dose inhaler with a spacer (Nebuhaler) and from a dry powder inhaler. Mucociliary clearance was measured by a non-invasive radioaerosol technique-bronchoscintigraphy6-which allows visualisation of the rate of disappearance of centrally deposited radioactivity from the large airways.
der inhalers increases. Methods The effect of different methods of administration of inhaled terbutaline on mucociliary clearance and forced expiratory volume in one second (FEVy) was assessed in 10 patients with asthma and 10 healthy subjects. Terbutaline (1 mg) was administered through a metered dose inhaler with a spacer (Nebuhaler) or a dry powder inhaler (Turbuhaler), or both treatments were given, in a four way double blind, double dummy trial. Mucociliary clearance was measured by bronchoscintigraphy. Results Clearance of radioactivity from the lobar bronchi increased in the asthmatic patients by a median of 32% after terbutaline was given by metered dose inhaler and 55% after a combined dose of 2 mg from both inhalers (1 mg from each) compared with placebo but by only 9% after 1 mg of terbutaline was given by a dry powder inhaler. In the healthy subjects mucociliary clearance increased by 51% when terbutaline was given by a dry powder inhaler, by 66% when given by a metered dose inhaler, and by 66% when given by both inhalers combined. The effect of terbutaline on FEV, was the same with each of the inhalers.
Conclusion Despite similar changes in FEV, with the two formulations terbutaline increased mucociliary clearance significantly in asthmatic and healthy subjects when inhaled from a metered dose inhaler whereas when it was inhaled from a dry powder inhaler its effect was significant only in healthy subjects. The reason for the difference in asthmatic subjects is unclear, but may be associated with differences in the deposition of terbutaline.
Mucociliary clearance, one of the most important defence mechanisms in the lung, is believed to be of special importance in patients with asthma, in the defence against allergens, infections, and irritants and for clearance of airway secretions.' It may, however, be impaired in such patients. 2 Attempts have been made to develop drugs which increase mucociliary clearance. fl,2
Adrenergic agonists have a dose dependent effect on the frequency of ciliary beats in vitro."' Studies of their effect on mucociliary clearance in humans have, however, had conflicting results.'2621 The drugs have a beneficial effect on lung function and are widely used to treat patients with asthma. They are often given by pressurised metered dose inhalers, which contain chlorofluorocarbons, although these are likely to be replaced in the future by metered dose inhalers with alternative propellants or with other portable devices for aerosolising drugs, such as dry powder inhalers. The terbutaline dry powder inhaler (Bricanyl Turbuhaler) is one such device. 22 We compared mucociliary clearance and forced expiratory volume in one second (FEVI) in healthy subjects and patients with mild to moderate bronchial asthma after inhalation of equal doses of terbutaline from a metered dose inhaler with a spacer (Nebuhaler) and from a dry powder inhaler. Mucociliary clearance was measured by a non-invasive radioaerosol technique-bronchoscintigraphy6-which allows visualisation of the rate of disappearance of centrally deposited radioactivity from the large airways.
Methods

SUBJECTS
Ten asthmatic subjects (five men and five women) and 10 healthy subjects (three men and seven women) participated in the study. All gave their fully informed consent and the study was approved by the medical ethics committee of Copenhagen. The median age of the asthmatic subjects was 36 5 years (range 22-69 years) and of the healthy controls 30 5 years (22-63 years). All of the asthmatic subjects had a history of repeated episodes of wheezing and dyspnoea, spontaneous peak flow variations of at least 20%, and an increase of at least 15% in FEV, after inhalation of a #2 agonist. All were currently being treated with an inhaled /2 agonist or steroid, or both (five with /2 agonists and steroid, four with #2 agonists alone, and one with steroids only). All drugs, except inhaled steroids, were withheld for the 12 hours preceding each study day. One asthmatic subject was a current smoker (30 pack years).
Five subjects (four asthmatic and one control) had stopped smoking 10-50 years before the study (1-18 pack years). The other 14 were lifelong non-smokers.
RADIOAEROSOL PROCEDURE
Subjects inhaled an ultrasonically nebulised (by a DeVilbiss 35 B) aerosol of albumin labelled with technetium-99m and isotonic saline6 according to the following technique. Inhalation, limited to a volume of 750 ml, started at residual volume. The radioaerosol was given as a bolus in the last 250 ml. The mass median aerodynamic particle diameter of the droplets from the nebuliser was 3-4 um (standard deviation 1 9 pm). The inhaled flow rate was monitored by a pneumotachograph and displayed on line on a computer screen. Subjects were instructed to keep the inhaled flow rate between 200 and 300 ml/second. After the 750 ml was inhaled they immediately exhaled forcefully without any holding of breath. They made 30 to 45 inhalations until about 700 counts/second was obtained from a large field ofview gammacamera.6 Immediately after the radioaerosol inhalation the initial distribution of deposited particles in the lungs was visualised by a posteriorly positioned camera. Subjects were seated against the camera in a chair that was specially designed to limit movement during the five minute counting periods. For the next two hours 10 gammacamera readings were obtained at regular intervals (for each 10-15 minutes). Each bronchoscintigram was made ofcomparable intensity by adjusting the acquisition time to compensate for the physical decay of 9'9Tc.6
Mucociliary clearance was assessed by independent inspection of the bronchoscintigrams by two authors (JM and SG), who were unaware ofwhich medication had been given. The assessment included counting the number of bronchi that could be identified and noting the time after inhalation when they could no longer be seen. In addition, a semiquantitative estimation of relative mucociliary clearance rates on each of the four study days was made for each subject and ranked as the slowest transport (4), second slowest (3), second fastest (2) , and fastest (1) .
In addition, mucociliary clearance was assessed by a conventional method. All images were recorded in 64 x 64 pixels and stored in the computer (General Electric Star). After correction for background and physical decay, clearance was derived from the radioaerosol retention at 120 minutes after the start in the whole lung and in the peripheral zone ( fig 1) as a percentage of the initial reading.
Krypton-81m ventilation scintigraphy was used to define the lung outline and lung zones ( fig 1) and to calculate a penetration ratio (the ratio of peripheral to central zone radioactivity due to 99mTc23). The zones were created after visual inspection of the central airways in bronchoscintigrams so that the central zone (17% of the total pixels) covered mainly the trachea and main bronchi; the intermediate zones (24% of the pixels) mainly lobar, segmental, and subsegmental bronchi; and the peripheral zones (59% of the pixels) the more peripheral bronchial generations. Each zone contained alveoli. As indicated by 8lmKr ventilation scintigraphy the proportions of alveolar volume in the central, intermediate, and peripheral zones were about 15%, 33%, and 51% respectively.
PROTOCOL
The effect of terbutaline sulphate on mucociliary clearance was studied by using a randomised, four part, double blind, double dummy protocol. The drug doses delivered on the four days by the metered dose inhaler and the dry powder inhaler were: placebo through both inhalers; 1 mg of terbutaline through the metered dose inhaler and placebo through the dry powder inhaler; placebo through the metered dose inhaler and 1 mg of terbutaline through the dry powder inhaler; and 1 mg of terbutaline through both inhalers. The placebo metered dose inhaler canister contained the usual lubricants and chlorofluorocarbons, whereas the placebo dry powder inhaler contained nothing. In this way the amounts of propellant and lubricant inhaled were constant on the four days. The drug or placebo was inhaled immediately after the deposition of the group.bmj.com on April 4, 2017 -Published by http://thorax.bmj.com/ Downloaded from 99M Tc albumin had been verified by the first bronchoscintigram. Both were administered as four puffs from the metered dose inhaler (0-25 mg of terbutaline per puff) attached to a pear shaped spacer (Nebuhaler, Astra) and two inhalations from the dry powder inhaler (0-5 mg of terbutaline per inhalation). The patients were instructed to take one deep slow inhalation from the residual volume after two puffs had been released from the metered dose inhaler into the spacer and to hold their breath for 10 seconds before exhalation. This was repeated one minute later. Inhalation from the dry powder inhaler was then performed as a forced deep inhalation from residual volume followed by holding of breath before exhalation. One minute later the inhalation was repeated.
LUNG FUNCTION All recordings were made on a pneumotachograph (Jaeger Transfer Screen). On each study day flow volume curves were obtained before the bronchoscintigraphic investigation to ensure that the FEVy varied by less than 15% between days. After each bronchoscintigraphic investigation-that is, 120 minutes after the inhalation of terbutaline or placebo-flow volume measurements were repeated. (fig 2) . In the asthmatic subjects there was a mean increase in FEV, of 0-6 litres (28%) above baseline 120 minutes after inhalation of terbutaline (p < 0-01). The increase was similar for terbutaline administered by the metered dose inhaler or the dry powder inhaler, or both. In the healthy subjects the mean increase in FEV, after terbutaline was only 0-2 litres (5%).
There was no significant difference among the penetration ratios on the four days in healthy or asthmatic subjects (table 1). None of the subjects had a productive cough during the examination. The median numbers of nonproductive coughs per study period in the asthmatic subjects did not differ significantly with the inhaler used: 0-5 with placebo in both inhalers, 0 3 with the drug given by metered dose inhaler, 01 with the drug given by dry powder inhaler, and 0-2 with the drug given by both inhalers. Coughing in the healthy subjects was negligible (median 0 1-0 2 coughs per study period).
BRONCHOSCINTIGRAPHY
The trachea, main bronchi, and the five lobar bronchi were visualised in all subjects on each of the four study days. The median number of segmental bronchi visualised was 13 after treatment with placebo, drug given by metered dose inhaler, and drug given by both inhalers and 12 after drug given by dry powder inhaler in the asthmatic subjects, and 11 after treatment with placebo and drug given by metered dose inhaler and 13 after drug given by dry powder inhaler and both inhalers in the healthy subjects. The median difference between the maximum and minimum number of segmental bronchi visualised in the subjects' four bronchoscintigrams was three (range one to six) in the asthmatic subjects and two (zero to 10) in the healthy subjects. Table 2 shows the individual estimates of mucociliary clearance of the central airways from inspection of the bronchoscintigrams. In the asthmatic subjects mucociliary clearance was similar after terbutaline given by dry powder inhaler and placebo and faster after terbutaline given by metered dose inhaler and by both inhalers. In the healthy subjects mucociliary clearance was fastest after terbutaline given by metered dose inhaler and by both inhalers, slower after terbutaline given by dry powder inhaler and slowest after placebo. The difference in mucociliary clearance between terbutaline given by metered dose inhaler and terbutaline given by both inhalers was not significant in either group. If terbutaline given by a dry powder inhaler deposits predominantly in the central airways it would be expected that centrally deposited 99mTc albumin would clear effectively.
However, the peripheral mucociliary clearance was significantly (and whole lung clearance non-significantly) smaller with the dry powder inhaler than with the metered dose inhaler in the asthmatic subjects. This delayed clearance of mucus from the periphery may affect subsequent transport through central airways by failing to supply mucus at the usual rates.8
The study of mucociliary clearance was carried out by using a new bronchoscintigraphic method, which allows regional mucociliary clearance to be visualised as the movement of radioactivity in selected central bronchi.67 We also used a conventional computer based measurement of total lung clearance at two hours. The conventional method is quantitative, whereas the bronchoscintigraphic method is semiquantitative. When the effects of terbutaline and placebo in the healthy subjects were compared both methods showed a significant increase in mucociliary clearance regardless of the method of administration of terbutaline. The bronchoscintigraphic method, however, showed that the radioactivity from the central bronchi was cleared slightly faster when terbutaline was administered by a metered dose inhaler or by both inhalers than by a dry powder inhaler alone. This information was not available with the conventional method, suggesting that the bronchoscintigraphic method may provide additional data not easily obtained by the conventional method.
When administered by a metered dose inhaler 1 mg of terbutaline doubled mucociliary clearance in both asthmatic and healthy subjects. This is consistent with previous findings in healthy subjects,"'4 but contrasts with some previous observations in asthmatic subjects.8 15 21 Generally, no effect has been seen after dosesof f2 agonists corresponding to 1 mg of terbutaline or less, whereas higher doses have caused some stimulation of mucociliary clearance. Our controlled study showed a clear stimulatory effect of only 1 mg of inhaled terbutaline on mucociliary clearance in asthmatic patients.
The asthmatic subjects were asymptomatic at the time of examination, so it was not surprising that mucociliary clearance on the day that placebo was given was similar in the asthmatic and the control subjects as reported in some,'7 1920 31 but not all,' 2 8 32 earlier studies.
In conclusion, we have shown that inhalation of 1 mg of terbutaline from a metered dose inhaler increased mucociliary clearance significantly in asthmatic patients and healthy subjects. When the same dose was inhaled from a dry powder inhaler the increase in mucociliary clearance was smaller, despite similar bronchodilatation, and was significantly above placebo values only in healthy subjects. The smaller effect of terbutaline given by dry powder inhaler on mucociliary clearance, while inhalation from a pressurised inhaler and a in asthmatic and healthy subjects after Effect of terbutaline on mucociliary clearance
